Suppressing immunity in advancing MS: too much too late, or too late for much?

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Neurology·2026

Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.

Neurology·2026

The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.

Neurology·2026

Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial.

Neurology·2026

Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.

Neurology·2026

Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.

Neurology·2026

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

NEJM evidence·2026

Heart Failure and Cancer: Incidence and Mortality Patterns, A Systematic Review and Meta-analysis.

European journal of heart failure·2026

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns.

European journal of haematology·2026

Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

Case reports in pediatrics·2026

OLFML2A expression in acute myeloid leukemia, with exploratory findings in acute lymphoblastic leukemia: Prognostic significance and re-analysis of public single-cell transcriptomic data.

Oncology letters·2026

Modulatory effects of S1QEL on OxLDL-induced metabolic alterations and inflammatory responses in human monocytes.

Immunometabolism (Cobham, Surrey)·2026

Related Experiment Videos

Suppressing immunity in advancing MS: too much too late, or too late for much?

Related Concept Videos

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.

The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.

Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial.

Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.

Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Heart Failure and Cancer: Incidence and Mortality Patterns, A Systematic Review and Meta-analysis.

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns.

Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

OLFML2A expression in acute myeloid leukemia, with exploratory findings in acute lymphoblastic leukemia: Prognostic significance and re-analysis of public single-cell transcriptomic data.

Modulatory effects of S1QEL on OxLDL-induced metabolic alterations and inflammatory responses in human monocytes.

Related Experiment Videos

Suppressing immunity in advancing MS: too much too late, or too late for much?

Related Concept Videos

Related Articles